Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
8.00
-0.03 (-0.37%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Kalaris Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -69.17 | -14.7 | -15.49 |
| Other Amortization | 38.02 | 0.89 | 1.99 |
| Asset Writedown & Restructuring Costs | - | - | 0.16 |
| Stock-Based Compensation | 0.9 | 0.15 | 0.27 |
| Other Operating Activities | 11.71 | 0.62 | -0.11 |
| Change in Accounts Payable | -1.03 | -0.4 | 1.83 |
| Change in Other Net Operating Assets | -1.1 | -0.69 | 1.57 |
| Operating Cash Flow | -20.67 | -14.13 | -9.78 |
| Short-Term Debt Issued | 19.97 | - | - |
| Long-Term Debt Issued | - | 6 | 4.3 |
| Total Debt Issued | 19.97 | 6 | 4.3 |
| Net Debt Issued (Repaid) | 19.97 | 6 | 4.3 |
| Issuance of Common Stock | 0 | - | 0.01 |
| Other Financing Activities | -2.42 | - | - |
| Financing Cash Flow | 19.14 | 14.24 | 12.78 |
| Net Cash Flow | -1.53 | 0.11 | 3 |
| Levered Free Cash Flow | -18.82 | -9.43 | - |
| Unlevered Free Cash Flow | -31.39 | -9.34 | - |
| Change in Net Working Capital | -0.05 | 1.07 | - |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.